241 related articles for article (PubMed ID: 24268211)
1. CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy Study: rationale and design of a randomized clinical trial.
Martinelli M; Rassi A; Marin-Neto JA; de Paola AA; Berwanger O; Scanavacca MI; Kalil R; de Siqueira SF
Am Heart J; 2013 Dec; 166(6):976-982.e4. PubMed ID: 24268211
[TBL] [Abstract][Full Text] [Related]
2. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
[TBL] [Abstract][Full Text] [Related]
4. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
[TBL] [Abstract][Full Text] [Related]
5. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of implantable cardioverter-defibrillators in patients with Chagas disease.
Barbosa MP; da Costa Rocha MO; de Oliveira AB; Lombardi F; Ribeiro AL
Europace; 2013 Jul; 15(7):957-62. PubMed ID: 23376978
[TBL] [Abstract][Full Text] [Related]
8. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
9. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
[TBL] [Abstract][Full Text] [Related]
10. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
11. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
Klein H; Auricchio A; Reek S; Geller C
Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.
Bardy GH; Lee KL; Mark DB; Poole JE; Packer DL; Boineau R; Domanski M; Troutman C; Anderson J; Johnson G; McNulty SE; Clapp-Channing N; Davidson-Ray LD; Fraulo ES; Fishbein DP; Luceri RM; Ip JH;
N Engl J Med; 2005 Jan; 352(3):225-37. PubMed ID: 15659722
[TBL] [Abstract][Full Text] [Related]
13. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
Prystowsky EN
Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
[TBL] [Abstract][Full Text] [Related]
14. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
Rassi FM; Minohara L; Rassi A; Correia LCL; Marin-Neto JA; Rassi A; da Silva Menezes A
JACC Clin Electrophysiol; 2019 Oct; 5(10):1213-1223. PubMed ID: 31648747
[TBL] [Abstract][Full Text] [Related]
15. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators.
Buxton AE; Lee KL; Fisher JD; Josephson ME; Prystowsky EN; Hafley G
N Engl J Med; 1999 Dec; 341(25):1882-90. PubMed ID: 10601507
[TBL] [Abstract][Full Text] [Related]
16. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
Schinkel AF
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
[TBL] [Abstract][Full Text] [Related]
19. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
20. Implantable cardioverter-defibrillator therapy for primary prevention of sudden cardiac death in patients with severe Chagas cardiomyopathy.
Cardinalli-Neto A; Nakazone MA; Grassi LV; Tavares BG; Bestetti RB
Int J Cardiol; 2011 Jul; 150(1):94-5. PubMed ID: 21497920
[No Abstract] [Full Text] [Related]
[Next] [New Search]
